OSCR

Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager.

Overview

Authors: Moon Jung Choi1,2, Eui Young So1,2, Bedia Akosman1,2, Young Eun Lee1,2, Alexander G Raufi1,2,3, Anthony M Reginato1,4, Clark C Chen1,5, Sean E Lawler1,3, Eric T Wong1,2,5, Olin D Liang1,2
ORCID iDs: Moon Jung Choi, Eui Young So, Young Eun Lee, Olin D Liang
  1. Legorreta Cancer Center of Brown University, Providence, RI 02903, USA
  2. Division of Hematology and Oncology, Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
  3. Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
  4. Division of Rheumatology, Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
  5. Department of Neurosurgery, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
Institutions: Brown University (United States); Rhode Island Hospital (United States)
Journal: Molecular therapy. Oncology, volume 34, issue 2, article 201201
Dates: received 12 January 2026; accepted 6 April 2026; published online 8 April 2026
Type: Research article · Language: English
License: CC BY-NC-ND
Identifiers: DOI 10.1016/j.omton.2026.201201 · PMID 42094336 · PMCID PMC13141506 · OpenAlex W4412855376
Open access: gold, a free copy (OpenAlex)
Preprint: doi:10.1101/2025.07.30.667708
Status: code on request
Categories: other condition (population), cellular / molecular (subfield)
Methods: Statistics, Preprocessing
Keywords: MT: Regular Issue, chimeric antigen receptor T, CAR T cell, immunotherapy, glioblastoma, tumor microenvironment, oncolytic adenovirus, immune cell engager, bispecific T cell engager, T cell recruitment, blood-brain barrier
Topic: CAR-T cell therapy research (Oncology, Medicine), according to OpenAlex
Funding: Brown University; Rhode Island Hospital; National Institutes of Health (P30GM145500); Brown University Warren Alpert Medical School
Citations: not cited yet (Europe PMC); 56 references in the paper

Abstract

The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.

Code

The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.

Data

No dataset and no data link were found in the paper.

Code and data availability statement

The paper has a code and data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:

  • it says that the data are available on request
  • it says that the code is available on request

Read it in the paper: doi.org/10.1016/j.omton.2026.201201.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 29 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 11 keywords, 4 funders, 56 references.

Cite

This paper

Choi, M. J., So, E. Y., Akosman, B., Lee, Y. E., Raufi, A. G., Reginato, A. M., Chen, C. C., Lawler, S. E., Wong, E. T., & Liang, O. D. (2026). Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager. Molecular therapy. Oncology, 34(2), 201201. https://doi.org/10.1016/j.omton.2026.201201

BibTeX

@article{choi2026enable,
author = {Choi, Moon Jung and So, Eui Young and Akosman, Bedia and Lee, Young Eun and Raufi, Alexander G and Reginato, Anthony M and Chen, Clark C and Lawler, Sean E and Wong, Eric T and Liang, Olin D},
title = {{Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager}},
journal = {Molecular therapy. Oncology},
year = {2026},
month = apr,
volume = {34},
number = {2},
pages = {201201},
publisher = {American Society of Gene \& Cell Therapy},
issn = {2950-3299},
doi = {10.1016/j.omton.2026.201201},
url = {https://doi.org/10.1016/j.omton.2026.201201},
pmid = {42094336},
pmcid = {PMC13141506}
}

RIS

TY - JOUR
AU - Choi, Moon Jung
AU - So, Eui Young
AU - Akosman, Bedia
AU - Lee, Young Eun
AU - Raufi, Alexander G
AU - Reginato, Anthony M
AU - Chen, Clark C
AU - Lawler, Sean E
AU - Wong, Eric T
AU - Liang, Olin D
TI - Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager
T2 - Molecular therapy. Oncology
J2 - Mol Ther Oncol
PY - 2026
DA - 2026/04/08
VL - 34
IS - 2
SP - 201201
SN - 2950-3299
PB - American Society of Gene & Cell Therapy
DO - 10.1016/j.omton.2026.201201
UR - https://doi.org/10.1016/j.omton.2026.201201
LA - en
ER -

CSL-JSON

{
"id": "10.1016/j.omton.2026.201201",
"type": "article-journal",
"title": "Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager",
"container-title": "Molecular therapy. Oncology",
"author": [
{
"family": "Choi",
"given": "Moon Jung"
},
{
"family": "So",
"given": "Eui Young"
},
{
"family": "Akosman",
"given": "Bedia"
},
{
"family": "Lee",
"given": "Young Eun"
},
{
"family": "Raufi",
"given": "Alexander G"
},
{
"family": "Reginato",
"given": "Anthony M"
},
{
"family": "Chen",
"given": "Clark C"
},
{
"family": "Lawler",
"given": "Sean E"
},
{
"family": "Wong",
"given": "Eric T"
},
{
"family": "Liang",
"given": "Olin D"
}
],
"container-title-short": "Mol Ther Oncol",
"volume": "34",
"issue": "2",
"page": "201201",
"DOI": "10.1016/j.omton.2026.201201",
"PMID": "42094336",
"PMCID": "PMC13141506",
"ISSN": "2950-3299",
"publisher": "American Society of Gene & Cell Therapy",
"URL": "https://doi.org/10.1016/j.omton.2026.201201",
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
8
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1016/j.cell.2026.05.026 [code]
The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.
Journal: Cell
In common: other condition, 8 references
[2] doi:10.1016/j.xcrm.2026.102967 [code]
Phase 1 study of intracranial T cell therapy with pemetrexed for refractory brain metastases and glioblastomas.
Journal: Cell reports. Medicine
In common: other condition, 4 references
[3] doi:10.1038/s41586-026-10641-1 [code]
Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.
Journal: Nature
In common: other condition, cellular / molecular, 4 references
[4] doi:10.1038/s41467-026-71021-x
Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.
Journal: Nature communications
In common: other condition, 4 references
[5] doi:10.1177/11795549261466431
Advances and Future Expectations in Oncolytic Virus Therapy for Glioblastoma: A Systematic Review of Clinical Trials.
Journal: Clinical Medicine Insights. Oncology
In common: other condition, 3 references
[6] doi:10.1002/advs.202522391
Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
In common: other condition, cellular / molecular, 3 references
[7] doi:10.1007/s11060-026-05635-y
From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma : FROST: multimodal treatment for GBM recurrence.
Journal: Journal of neuro-oncology
In common: other condition, 3 references
[8] doi:10.1080/2162402x.2026.2656053
PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma.
Journal: Oncoimmunology
In common: other condition, cellular / molecular, 2 references
[9] doi:10.1126/sciadv.aeb1237
Magnetically actuated nanoantennas for wireless glioblastoma therapy.
Journal: Science advances
In common: other condition, 2 references
[10] doi:10.1172/jci195639
Therapeutic delivery of microRNAs discovered to target deregulated glioblastoma pathways inhibits tumor growth in mice.
Journal: The Journal of clinical investigation
In common: other condition, cellular / molecular, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.